Skip to main content
International Journal of Women's Dermatology logoLink to International Journal of Women's Dermatology
. 2020 Oct 12;7(2):217–223. doi: 10.1016/j.ijwd.2020.09.010

Impact of COVID-19 pandemic on dermatology practices: Results of a web-based, global survey

Shashank Bhargava a, Charles McKeever b, George Kroumpouzos c,d,e,
PMCID: PMC7550183  PMID: 33072835

Highlights

  • Survey showed a decrease in in-person consultations, hospital service and procedures.

  • Survey showed an increase in TD use.

  • >1000 COVID-19 cases in the country: the most important predictor of future TD use.

  • The pandemic appears to have contributed to increased TD use in the long-run.

Keywords: COVID-19, Dermatology, Practice, Procedures, Teledermatology, Hospital service

Abstract

The spectrum and magnitude of changes in dermatology practice induced by the COVID-19 pandemic have not been adequately studied.

Objective

This study aimed to assess the immediate and long-term effects of the pandemic on dermatology practice on a large scale, including the clinical activity of participants, frequency and types of procedures used, and teledermatology (TD) use.

Methods

This web-based, global survey included 733 dermatologists. The primary outcomes are percentages of respondents providing in-person consultations, hospital service, and TD and performing procedures. Factors in logistic regression models that may influence the odds ratio (OR) for TD use during pandemic and for future use also were analyzed.

Results

The percentages of respondents providing in-person consultations (46.6% vs. 100% before the pandemic) and hospital service (27% vs. 52.8% before the pandemic) as well as performing procedures (25.6% vs. 100% before the pandemic) decreased, whereas practicing TD increased three-fold (75.2% vs. 26.1% before the pandemic) during the pandemic (p < .001 for each). Practice location was associated with TD use during the pandemic and with its expected use in the future (p < .001 for both), with North American respondents indicating the highest use. TD use during the pandemic showed a positive correlation with TD use before the pandemic, performing procedures and, more specifically, with biopsies of suspicious pigmented lesions during the pandemic (p < .001 for each). TD use before the pandemic was the most powerful predictor of TD use during the pandemic (OR: 16.47; 95% confidence interval, 7.12–38.06). More than two third of participants (68.6%) expect to use TD in the future. The factor with the largest increase in OR on the expectation of future TD use was >1000 COVID-19 cases in the country (OR: 3.80; 95% confidence interval, 2.33–6.21).

Conclusion

This survey indicates a profound immediate effect of the pandemic on dermatology practice. The pandemic appears to have substantially contributed to an increased use of TD in the long run.

Introduction

Background

The COVID-19 pandemic is affecting health care systems across the globe (Emanuel et al., 2020, Mahmood et al., 2020). Dermatology has faced unprecedented challenges, including a reduction in nonessential visits and procedures (Gisondi et al., 2020, Kumar et al., 2020, Wollina, 2020). To contain COVID-19, in-person consultations have been reduced and the implementation of teledermatology (TD) has increased (Fahmy et al., 2020, Litchman and Rigel, 2020, Muddasani et al., 2020). Dermatologists served on the frontline in several parts of the globe (Bhargava et al., 2020c; Zheng et al., 2020) and played an important role in enhancing preventive measures (Goren et al., 2020, Tao et al., 2020, Yan et al., 2020). However, dermatologists face a shortage of personal protective equipment in the health care system (Bhargava et al., 2020a, Goldust et al., 2020a). Although the immediate effects of the pandemic, including a decrease in patient visits and postponing nonessential procedures, have been documented in a few reports (Litchman and Rigel, 2020, Zheng and Lai, 2020), the long-term effects have not been assessed. The spectrum and magnitude of changes in dermatology practice during the COVID-19 pandemic also have not been evaluated on a large scale (Temiz et al., 2020).

Objectives

We assessed dermatology practices on a large scale during the pandemic, taking into account practice setting and population density, as well as conditions in each participant’s country (i.e., number of COVID-19 cases and lockdown status). Our study addresses the clinical activity of participants, frequency and types of procedures performed, and TD use. We developed logistic regression models to identify factors that influence the odds ratio (OR) for TD use during the pandemic and for the future.

Methods

Study design

This is a web-based, cross-sectional study.

Survey instrument

Development of the survey went through the stages of item generation, item reduction, formatting, and composition. The questionnaire was then pilot tested in the investigators’ academic dermatology departments to ensure proper flow, salience, and acceptability of the questions. During the pilot phase, we ensured that each question was understood the same way by dermatologists practicing in different continents. Questions relevant to dermatology practice specifics that are common in one geographic area but uncommon in another were eliminated during pilot testing.

Cognitive testing was further evaluated and refinements were made if deemed appropriate. The final instrument included sets of questions on demographics, practice specifics before and during the pandemic, and hospital service. The instrument also included questions relevant to the health care system, training of residents/fellows, and other questions (e.g., mental health status of participants during the pandemic) that are reported separately.

Survey administration

The survey instrument was formatted in Google forms and distributed electronically between April 1 and April 20, 2020 to the investigators’ contacts on social media sites, specifically to board-certified dermatologists. Participants could access the survey via a link that was provided. The survey instrument was disseminated twice, the data collection period was extended, and reminder messages were sent to increase participation. Two questions relevant to the number of biopsies performed and postponed during the pandemic were added to the instrument before the second dissemination. This was an anonymous survey; there was no process of data linkage, and neither recording nor dissemination generated identifiable information.

Variables

The primary outcomes are percentages of respondents providing in-person consultations, hospital service, and TD and performing procedures during the pandemic. Factors in logistic regression models that may influence the OR for TD use during the pandemic and for future use were analyzed.

Statistical analysis

A total of 1120 dermatologists were surveyed, and 746 responded (response rate: 66.6%). Thirteen respondents were excluded because they were not board-certified dermatologists and/or missed essential demographic questions and/or responded to <80% of the questions for which they qualified. This left a sample of 733 respondents for analysis. Frequencies and percentages of respondents in the subgroups within each categorical variable are provided. Numerical data are presented with median and interquartile range (IQR) or mean, as appropriate. Pairs of categorical variables were assessed for association with the χ2 or McNemar test. A Mann-Whitney (Wilcoxon rank sum) test was used to assess the relationships between two divisions of ordinal variables as defined by a binary covariant. The relationship between the only two continuous variables was characterized by the Spearman correlation coefficient. The threshold of significance for p values was adjusted for multiple comparisons using a false discovery rate (cutoff rate; p < .05; Chen et al., 2017).

Logistic regression models were generated for each of the following binary dependent variables: TD use during the pandemic and future TD use. Models were created through forward selection, in which candidate independent variables found to be associated with the outcome variable at p ≤ .0001 were entered in order from the smallest to larger p values. Once entered into the model, variables with an OR estimated at p > .05 were dropped. Nested models were compared using the log likelihood test, and those that were not nested were compared on model specification, Akaike information criterion, Hosmer-Lemeshow goodness-of-fit, variance inflation factor, tolerance, and condition index (Tolles and Meurer, 2016). When variables with >3 categories were found to fail the retention criterion or to have categories that did not differ significantly in their estimated OR, they were recoded into binary variables, which were then tested for inclusion. In the final best models, the OR that the dependent binary variable = 1 (“yes”) is given by the baseline OR (value of _cons) multiplied by the OR of each independent binary variable when they are = 1 (“yes”). Statistical analysis was performed using Stata, version 15.1 (StataCorp, College Station, TX).

Results

Descriptive data

Practice demographic characteristics are shown in Table 1.

Table 1.

Practice demographics.

Characteristic Survey Distributiona
n (%)
Years in practice (n = 733)
 ≤10 330 (45.0)
 11–20 205 (28.0)
 >20 198 (27.0)



Location (continent; n = 733)
 Asia 349 (47.6)
 North Americab 137 (18.7)
 Central/South America 131 (17.9)
 Europe 102 (13.9)
 Other 14 (1.9)



Population density of practice (n = 733)
 Urban 576 (78.6)
 Suburban 137 (18.7)
 Rural 20 (2.7)



Practice Setting (n = 733)
 Private 346 (47.2)
 Private and hospital 249 (34.0)
 Tertiary hospital 91 (12.4)
 General hospital 47 (6.4)
a

Percentages are rounded to the decimal place.

b

Group includes predominantly U.S. participants.

Outcome data

Table 2 displays practice specifics before and during the pandemic. Table 3 shows data regarding TD use before and during the pandemic and in the future. Regarding pandemic conditions, 360 (49.1%), 197 (26.9%), and 176 (24.0%) participants reported ≤1000, 1001 to 10,000, and 10,001 to 50,000 COVID-19 cases in their country, respectively. Furthermore, 486 participants (66.3%) responded that their area was in total lockdown whereas 246 participants (33.6%) were in partial lockdown.

Table 2.

Practice specifics before and during the pandemic.

Before the pandemic
During the pandemic
Characteristic Survey distributiona
n (%)
Characteristic Survey distributiona
n (%)
Activity (n = 733) Activity (n = 733)
 Face-to-face consultations only 542 (73.9)  Face-to-face consultations only 68 (9.3)
 TD consultations only 0 (0)  TD consultations only 277 (37.8)
 Face-to-face and TD consultations 191 (26.1)  Face-to-face and TD consultations 274 (37.3)
 Inactive 0 (0)  Inactive 114 (15.6)
Patients seen per week (n = 733) Patients seen per week (n = 286)
 ≤50 109 (14.9)  ≤20 180 (62.9)
 51–100 199 (27.2)  21–40 73 (25.5)
 101–150 180 (24.6)  41–60 14 (4.9)
 151–200 99 (13.5)  61–80 10 (3.5)
 201–250 60 (8.2)  80–100 6 (2.1)
 >250 86 (11.7)  >100 3 (1.1)
Procedures per week (n = 733) Performing procedures? (n = 733)
 ≤20 257 (35.1)  Yes 188 (25.6)
 21–40 320 (43.7) Type of procedure
 41–60 94 (12.8)  Biopsy 155 (82.4)
 61–80 33 (4.5)  Mohs surgery 61 (32.4)
 81–100 16 (2.2)  Cryotherapy 53 (28.2)
 >100 13 (1.8)  Electrosurgery 53 (28.2)
 Incision and drainage 20 (10.6)
 Excision 19 (10.1)

TD, teledermatology.

a

Percentages are rounded to the decimal place.

Table 3.

Teledermatology use.

TD before the pandemic Survey distributiona
n (%)
Practicing (n = 733)
 Yes 191 (26.1)



Patients (n = 191)
 New 8 (4.2)
 Follow-up 112 (58.6)
 Both 71 (37.2)



Consultations per week (n = 191)
 ≤20 178 (93.2)
 21–40 10 (5.2)
 41–60 3 (1.6)



TD during the pandemic
Practicing (n = 733)
 Yes 551 (75.2)



Patients (n = 551)
 New 11 (2.0)
 Follow-up 171 (31.0)
 Both 369 (67.0)



Consultations per week (n = 551)
 ≤20 457 (82.9)
 21–40 72 (13.1)
 >40 22 (4.0)



TD types (n = 551)
 Video 323 (58.6)
 Online consultation 199 (36.1)
 Phone call 220 (39.9)
Other 1 (0.2)



Platform (n = 551)
 WhatsApp 269 (48.8)
 Zoom 88 (16.0)
 Facetime 83 (15.1)
 Facebook messenger 64 (11.6)
 Viber 23 (4.2)
 Other 74 (13.4)



Are you able to bill for virtual visits? (n = 551)
 Yes 251 (45.6)
 No 233 (42.3)
 Sometimes 67 (12.2)



Has your medical board/council or other authority (eg, CMS) permitted virtual consultations/relaxed HIPAA compliance related to telehealth for the duration of the pandemic? (n = 733)
 Yes 476 (64.9)
 No 41 (5.6)
 Do not know 216 (29.5)



Future TD use
Do you think you will use TD in the future? (n = 733)
 Yes 503 (68.6)
 No 213 (29.1)
 Unsure 17 (2.3)



If yes, when will you use TD? (n = 503)
 As part of my regular practice 402 (79.9)
 During the COVID-19 pandemic 294 (58.4)
 During other health system disruptions 262 (52.1)



Anticipated consultations per week (n = 503)
 ≤20 372 (74.0)
 21–40 98 (19.5)
 >40 33 (6.6)

CMS, Centers for Medicare and Medicaid Services; HIPAA, Health Insurance Portability and Accountability Act of 1996; TD, teledermatology.

a

Percentages are rounded to the decimal place.

Practice during the pandemic

Regarding the clinical activity of participants during the pandemic (Table 2), 37.8% of respondents provided only TD, 37.3% a combination of TD and in-person consultations, 9.3% solely in-person consultations, and 15.6% stopped clinical activity. Of those who stopped working, 79.8% were located in geographic locations on total lockdown (p < .001 for partial vs. total lockdown). More than one fourth of respondents were providing hospital services (27% vs. 52.8% before the pandemic; p < .001). The majority of participants (446 of 773; 60.8%) responded that outpatient dermatology clinics were discontinued at the hospital. Most participants who were providing hospital services (223 of 287; 77.7%) were seeing only emergencies at the hospital. The majority of participants (62.9%) were consulting ≤20 cases per week. Only 1.04% of respondents were consulting >100 cases per week, compared with 58% before the pandemic (p < .001).

Only a quarter of respondents were performing procedures. Biopsy was the most common procedure, followed by micrographic (Mohs) surgery (82.4% and 32.4%, respectively, of those performing procedures). Excision was even less common (10.1%), and only 7.4% of participants performing procedures were doing cosmetic procedures. The median value for biopsies of suspicious pigmented lesions taken per week by dermatologists providing face-to face consultations during the pandemic (n = 220) was 1 (IQR, 0–3). The median value for biopsies postponed per week during the pandemic (n = 386) was 5 (IQR, 3–20). The mean values for biopsies taken (n = 88) and postponed (n = 94) in the North American group were 4.95 and 21.2, respectively.

Teledermatology

There was an almost 3-fold increase in the number of dermatologists practicing TD during compared with before the pandemic (75.2% vs. 26.1%; p < .001; Table 3). Only 6.8% of respondents were consulting >20 cases per week via TD before compared with 17.1% during the pandemic (p < .001). The percentage of respondents using TD for both follow-up and new patients increased from 37.2% before to 67% during the pandemic (p < .001). More than two thirds of participants (68.6%) expect to practice TD in the future, the majority (79.9%) as part of their regular practice. Respondents anticipated more consultations in the future than during the pandemic (P = .002 for >20 consultations/week). WhatsApp was the most common platform, not only in the total number of participants (Table 3) but also across all continents (Europe: 62.4%; Asia: 62.6%; North America: 39.4%; Central/South America: 36.7%). Use of WhatsApp was more common in Europe and Asia than in North America and Central/South America (p < .001).

Comparative statistics

Comparative statistics are summarized in Table 4. Procedures were associated with years in practice, location, and the number of procedures per week before the pandemic (p < .001 for all). The number of biopsies for suspicious pigmented lesions performed during the pandemic was associated with the number of patients seen per week before and during the pandemic, North American location, and the number of biopsies postponed per week (p < .001 for all). Practice location was associated with TD use during the pandemic and with its expected use in the future (p < .001 for both), with North American respondents indicating the highest use.

Table 4.

Statistically significant associations.a

Practice specifics during the pandemic p-valueb Group analyses, n (%)c
Patients/wk during the pandemic (n = 286) Patients/wk before the pandemicd <.001



Performing procedures during the pandemic (n = 733) Years in practice <.001 Y/GTe: <10 (17.9); 11–20 (28.8); >20 (35.3)
<10 vs. 11–20 (p = .019)
Continent <.001 Y/GT: NA (58.4); E (47.0); CSA (30.5); A (4.0)
χ2 test: NA vs. CSA (p < .001); E vs. CSA (p = .009), CSA vs. A (p < .001)
Procedures/wk before the pandemicd <.001 <40 (21.7); >40 (40.4)



Incision and drainage (n = 188) Continent <.001 Y/GT: A (42.8); E (12.5); NA (6.2); CSA (2.5)
A vs. NA (p < .001)



No. of biopsies of suspicious pigmented lesions per week (n = 188) Continent <.001f NA Median (IQR), 2 (0–50)
A + CSA + E Median (IQR), 0 (0–20)
Patients/wk before the pandemic < .001f >100 Median (IQR), 2 (0–50)
≤100 Median (IQR), 0 (0–20)
Patients/wk during the pandemic < .001f >20 Median (IQR), 4 (0–30)
≤20 Median (IQR), 1 (0–20)
Number of biopsies postponed/wk <.001 g



TD use
TD use before the pandemic (n = 733) Continent <.001 Y/GT: E (38.6); A (26.6); CSA (25.9); NA (16.7)
E vs. A (p < .019); A vs. NA (p = .022)



TD use during the pandemic (n = 733) Continent <.001 Y/GT: NA (89.7); E (82.1); CSA (70.2); A (69.4)
NA vs. CSA (p < .001); E vs. CSA (p = .036)
TD use before the pandemicd <.001
Performing procedures during the pandemic <.001
Taking biopsy during the pandemic <.001



Future TD use (n = 733) Continent <.001 Y/GT: NA (83.9); CSA (77.1); E (63.4); A (60.3)
E vs. CSA (p = .022)
Patients/wk before the pandemic <.001 Y/GT: <100 (77.8); 101–200 (67.3); >200 (59.4)
TD use before the pandemic <.001
TD use during the pandemic <.001
Lockdown <.001 Y/GT: Partial (76.8); total (64.4)

A, Asia; CSA, Central and South America; E, Europe, GT, group total; HIMG, hospital-issued management guidelines; IQR, interquartile range; NA, North America; TD, teledermatology; Y/GT, yes/group total.

a

χ2 test performed unless otherwise noted.

b

Only statistically significant p-values are shown.

c

Refers to the groups of variables in the second column.

d

McNemar test.

e

Percentage rounded to the decimal place. Percentages of groups are listed in descending order.

f

Wilcoxon rank-sum (Mann Whitney) test.

g

Spearman rank correlation.

TD use during the pandemic showed a positive correlation with TD use before the pandemic, performing procedures, and more specifically with biopsies of suspicious pigmented lesions during the pandemic (p < .001 for each). Future TD use showed a positive correlation with the number of patients seen per week before the pandemic and with TD use before and during the pandemic (p < .001 for each).

Logistic regression models

The results from the logistic regression models are summarized in Table 5. TD use before the pandemic was the most powerful predictor of TD use during the pandemic (OR: 16.47; 95% confidence interval, 7.12–38.06; Table 5, Model 1). Other variables significantly contributing to the OR of TD use during the pandemic were North American practice location and continuing to perform procedures. The presence of >1000 COVID-19 cases in the respondent’s country had the largest effect on the OR of expecting future TD use (OR: 3.80; 95% confidence interval, 2.33–6.21; Table 5, Model 2). Other factors increasing this OR were TD use before the pandemic, using TD for both follow-up and new patients, and TD video visits during the pandemic.

Table 5.

Logistic regression models.

Model Dependent variable Independent variables LR χ2 OR SE Za p-value 95% CI
1 TD during the pandemic 126.98
TD before the pandemic 14.05 6.04 6.15 <.001 6.05–32.64
North America 2.99 0.96 3.43 .001 1.60–5.60
Performing procedures during the pandemic 2.12 0.58 2.74 .006 1.24–3.64
Future TD 1.77 0.35 2.93 .003 1.21–2.60
_consb 1.06 0.16 0.37 .708 0.78–1.44



2 Future TD use 82.00
>1000 COVID-19 cases in country 3.80 0.95 5.35 <.001 2.33–6.21
TD before the pandemic 2.51 0.66 3.51 <.001 1.50–4.21
TD during the pandemic: Both follow-up and new patients 2.03 0.48 3.01 .002 1.28–3.23
TD type during the pandemic: Virtual (video) consultation 1.98 0.47 2.82 .004 1.23–3.18
_cons 0.55 0.13 –2.58 .009 0.35–0.86

CI, confidence interval; HIMG, hospital-issued management guidelines; LR, likelihood ratio; OR, odds ratio; PPE, personal protective equipment; SE, standard error; TD, teledermatology.

All LR χ2p < .0001.

Numbers are rounded to two decimal places in all but the p-value column (three decimal places).

a

z defined as OR:SE.

b

_cons estimates baseline odds.

Discussion

Impact on clinical activity

The COVID-19 pandemic is having a huge impact on dermatology practice, including a significant reduction in in-person consultations and nonemergency procedures, as well as a remarkable increase in TD use (Goldust et al., 2020b, Litchman and Rigel, 2020, Wollina, 2020). Our study confirms these trends by showing a 53% reduction in the number of dermatologists providing face-to-face consultations and a 49.1% increase in TD consultations. The survey also indicates that 15.6% of dermatologists stopped delivering care during the pandemic and were more likely to practice in areas of total rather than partial lockdown (Gorrepati and Smith, 2020).

Impact on procedures performed

Only one fourth of dermatologists continued performing procedures during the pandemic (Table 2). Biopsy was the most common, followed by Mohs surgery. Excision was performed less often than Mohs surgery, which possibly indicates a priority on treating high-risk tumors (i.e., performing Mohs surgery for high-risk squamous cell carcinoma while deferring treatment of low-risk tumors and deciding on a case-by-case basis for intermediate-risk tumors) per the current guidelines on management of patients with skin cancer during the pandemic (Baumann et al., 2020, British Association of Dermatologists and British Society for Dermatological Surgery, 2020, Geskin et al., 2020, National Comprehensive Cancer Network, 2020a). Cosmetic procedures were uncommon. Although this is due mainly to deferring elective procedures (Galadari et al., 2020), it might also indicate decreased patient interest in such treatments during the crisis (Guzman and Barbieri, 2020).

The number of biopsies for suspicious pigmented lesions per week (median: 1; IQR, 0–30) was associated with the number of patients seen per week both before and during the pandemic (p < .001 for both; Table 5). A median of five biopsies per week (IQR, 3–20) were postponed. Neither the numbers of biopsies per week performed nor those postponed were associated with TD use. The North American group had both a lower mean for biopsies taken (4.95) and a higher mean for biopsies postponed (21.2) compared with a U.S. group (7.7 and 10.7, respectively) in a study performed during the pandemic (Litchman and Rigel, 2020). This is possibly due to the data having been collected at an earlier stage in the pandemic (i.e., through the week of March 16 in the comparative study). The correlation between the numbers of biopsies for pigmented lesions performed and postponed may indicate that dermatologists have been focusing more on not missing a melanoma diagnosis than on keratinocytic carcinomas during this pandemic (Der Sarkissian et al., 2020, National Comprehensive Cancer Network, 2020b).

Impact on hospital service

COVID-19 has a considerable impact on dermatology care provided in the hospital setting (Chen et al., 2020). In this study, outpatient dermatology clinics were discontinued at the local hospital (60.8%), and the number of dermatologists providing hospital service decreased during compared with before the pandemic. This disruption is probably due to social distancing measures and concerns that dermatology examinations may be a vector of COVID-19 transmission (Cengiz et al., 2020, Kwatra et al., 2020). Our findings align with reports of dermatology specialty clinics being reduced or postponed indefinitely (Radi et al., 2020), and wards turned into COVID-19 care and quarantine centers in developing countries (Kumar et al., 2020).

Impact on teledermatology use

TD provides patients ongoing access to dermatologic care and affords a safer way to evaluate patients, including those with confirmed or suspected COVID-19 infection (Madigan et al., 2020). Our study showed a 49.1% increase in the number of participants providing TD consultations during the pandemic and a significantly increased number of participants using TD for both new and follow-up patients. Relaxed compliance with the Health Insurance Portability and Accountability Act of 1996 was allowed by state medical boards and other authorities, as indicated by 64.9% of our respondents. Similar initiatives taken by federal authorities could have enhanced the implementation of TD (Azar, 2020, Bressler et al., 2020). Furthermore, TD reimbursement improved during the pandemic, as evidenced by the fact that most states currently have parity laws that reimburse telehealth as a regular office visit whereas only 16 states had such laws before the pandemic (American Telemedicine Association, 2019). Recent advances in communication technology via modern video-conferencing equipment are facilitating telehealth. Innovations including real-time diagnostic data transfer and cloud technology are enhancing telehealth and making it more popular (Bhargava et al., 2020b).

The dramatic increase in TD use reflects a need to continue providing dermatology care for nonemergent cases and an expectation that TD can significantly reduce the risk of COVID-19 transmission (Gupta et al., 2020, Lee et al., 2020, Sheriff et al., 2020, Temiz et al., 2020, Villani et al., 2020). In this study, video visit was the most common type of TD during the pandemic, and the WhatsApp messenger was the most common platform used (Jakhar et al., 2020). This platform allows users to communicate via text/voice messages, photos, and videos. A recent report of WhatsApp use during the pandemic highlighted the strength of this platform and instant text messaging in health care providers’ activity (Duong et al., 2020). Despite a high percentage (42.3%) of nonreimbursement, more than two thirds of respondents (68.6%) expect to use TD in the future, the majority (68.6%) as part of their regular practice. Respondents anticipated more consultations in the future than during the pandemic.

Predictors of teledermatology use

Logistic regression analysis showed that TD use before the pandemic was the most powerful predictor of TD use during the pandemic, followed by North American practice location and performing procedures during the pandemic. The last association may indicate that providers who perform many procedures would prefer seeing medical dermatology cases and/or procedure follow-ups via TD. The factor with the largest increase in OR on the expectation of future TD use was >1000 COVID-19 cases in the participant’s country. This finding highlights the profound effect of the COVID-19 pandemic on future TD use.

Other factors in the logistic model that increased the OR for future TD use were TD use before the pandemic and TD use for both follow-up and new patients and video visits during the pandemic. Dermatologists who used TD for new patients during the pandemic could have accommodated more appointment requests using TD, and video TD consultations may offer an advantage in physician–patient interactions compared with other TD forms (e/g/, phone call). T, which may explain why dermatologists who used TD for new patients and/or provided video TD consultations are more likely to plan to use TD in the future. Our finding aligns with reports of higher satisfaction for video than store-and-forward TD among dermatologists before the pandemic (Marchell et al., 2017, Mounessa et al., 2018).

Limitations

We had only a small number of respondents from Africa and Australia. Participants with lower patient volumes, especially in areas of total lockdown, may have had more time to respond. To minimize this bias, we sent reminder messages to invited participants on weekends. Recall biases cannot be excluded, but the large sample size and representative distribution possibly diminished these biases. No-response biases cannot be excluded, but access to social media and demographics did not differ between the groups of respondents and nonrespondents.

Conclusion

This global survey indicates a profound immediate effect of the COVID-19 pandemic on dermatology practices, including a decreased number of visits and nonessential procedures and a remarkable increase in TD use. The logistic regression models in our study suggest factors that might influence the OR for TD use during the pandemic and for the future. This pandemic appears to have substantially contributed to an increased use of TD in the long term.

Acknowledgments

Acknowledgments

The authors are thankful to Prof. Evangeline Handog and Dr. Mohamad Goldust for their assistance with the data collection.

Conflicts of Interest

None.

Funding

None.

Study Approval

N/A.

References

  1. American Telemedicine Association. 2019 State of the States: Cover-age & reimbursement [Internet]. 2019 [cited 2020 August 10]. Available at: https://cdn2.hubspot.net/hubfs/5096139/Files/ Thought Leadership_ATA/2019 State of the States summary_final.pdf.
  2. Azar AM II. Waiver or modification of requirements under Section 1135 of the Social Security Act [Internet]. 2020 [cited 2020 June 16]. Available at: https://www.phe.gov/emergency/news/healthactions/section1135/Pages/covid19-13 March20.aspx.
  3. Baumann B.C., MacArthur K.M., Brewer J.D., Mendenhall W., Barker C.A., Etzkorn J.R. Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer. 2020;126(17):3900–3906. doi: 10.1002/cncr.32969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bhargava S., Gupta M., Kroumpouzos G. Protection comes at a cost: Doctor’s life inside personal protection equipment. Dermatol Ther. 2020 doi: 10.1111/dth.13758. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhargava S., Negbenebor N., Sadoughifar R., Ahmad S., Kroumpouzos G. Global impact on dermatology practice due to COVID-19. Clin Dermatol. 2020 doi: 10.1016/j.clindermatol.2021.01.017. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bhargava S., Rokde R., Rathod D., Kroumpouzos G. Employing dermatologists on the frontline against COVID-19: All hands on deck. Dermatol Ther. 2020 doi: 10.1111/dth.13420. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bressler M.Y., Siegel D.M., Markowitz O. Virtual dermatology: A COVID-19 update. Cutis. 2020;105(4):163–164. E2. [PubMed] [Google Scholar]
  8. British Association of Dermatologists and British Society for Dermatological Surgery. COVID-19 – Skin cancer surgery guidance. Clinical guidance for the management of skin cancer patients during the coronavirus pandemic [Internet]. 2020 [cited 2020 June12]. Available at: http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=6658.
  9. Cengiz F.P., Emiroglu N., Bahali A.G., Dizman D., Taslidere N., Akarslan T.C. Which dermatology patients attend to dermatology outpatient clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them? Dermatol Ther. 2020 doi: 10.1111/dth.13470. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chen S.Y., Feng Z., Yi X. A general introduction to adjustment for multiple comparisons. J Thorac Dis. 2017;9(6):1725–1729. doi: 10.21037/jtd.2017.05.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen Y., Pradhan S., Xue S. What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus? J Am Acad Dermatol. 2020;82(4):1034. doi: 10.1016/j.jaad.2020.02.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Der Sarkissian S.A., Kim L., Veness M., Yiasemides E., Sebaratnam D.F. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):e29–e30. doi: 10.1016/j.jaad.2020.04.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Duong T.A., Velter C., Rybojad M., Comte C., Bagot M., Sulimovic L. Did Whatsapp® reveal a new cutaneous COVID-19 manifestation? J Eur Acad Dermatol Venereol. 2020;34(8):e348–e350. doi: 10.1111/jdv.16534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Emanuel E.J., Persad G., Upshur R., Thome B., Parker M., Glickman A. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020;382(21):2049–2055. doi: 10.1056/NEJMsb2005114. [DOI] [PubMed] [Google Scholar]
  15. Fahmy D.H., El-Amawy H.S., El-Samongy M.A., Fouda A.A., Soliman S.H., El-Kady A. COVID-19 and dermatology: A comprehensive guide for dermatologists. J Eur Acad Dermatol Venereol. 2020;34(7):1388–1394. doi: 10.1111/jdv.16545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Galadari H., Gupta A., Kroumpouzos G., Kassir M., Rudnicka L., Lotti T. COVID 19 and its impact on cosmetic dermatology. Dermatol Ther. 2020 doi: 10.1111/dth.13822. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gisondi P., Piaserico S., Conti A., Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020;34(6):1196–1201. doi: 10.1111/jdv.16515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Geskin L.J., Trager M.H., Aasi S.Z., Bickers D.R., Carvajal R.D., Nghiem P. Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):295–296. doi: 10.1016/j.jaad.2020.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Goldust M., Kroumpouzos G., Murrell D., Jafferany M., Lotti T., Wollina U. Use of face masks in dermatology department during the COVID-19 outbreak. Dermatol Ther. 2020 doi: 10.1111/dth.13521. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goldust M., Kroumpouzos G., Murrell D., Rudnicka L., Das A., Lotti T. Update on COVID-19 effects on dermatology specialty. Dermatol Ther. 2020 doi: 10.1111/dth.13523. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Goren A., Rathod D., Kroumpouzos G., Jafferany M., Goldust M. Safety measures in dermatology help minimize spread of COVID-19. Dermatol Ther. 2020 doi: 10.1111/dth.13773. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gorrepati P.L., Smith G.P. Evaluating the dermatology communities' public health response to COVID-19. Dermatol Ther. 2020 doi: 10.1111/dth.13775. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gupta R., Ibraheim M.K., Doan H.Q. Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray. J Am Acad Dermatol. 2020;83(1):168–169. doi: 10.1016/j.jaad.2020.04.080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Guzman A.K., Barbieri J.S. Analysis of dermatology-related search engine trends during the COVID-19 pandemic: Implications for patient demand for outpatient services and telehealth. J Am Acad Dermatol. 2020;83(3):963–965. doi: 10.1016/j.jaad.2020.05.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jakhar D., Kaul S., Kaur I. WhatsApp messenger as a teledermatology tool during coronavirus disease (COVID-19): From bedside to phone-side. Clin Exp Dermatol. 2020;45(6):739–740. doi: 10.1111/ced.14227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kumar S., Bishnoi A., Vinay K. Changing paradigms of dermatology practice in developing nations in the shadow of COVID-19: Lessons learnt from the pandemic. Dermatol Ther. 2020 doi: 10.1111/dth.13472. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kwatra S.G., Sweren R.J., Grossberg A.L. Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits. J Am Acad Dermatol. 2020;82(5):e179–e180. doi: 10.1016/j.jaad.2020.03.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lee I., Kovarik C., Tejasvi T., Pizarro M., Lipoff J.B. Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol. 2020;82(5):1213–1214. doi: 10.1016/j.jaad.2020.03.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Litchman G.H., Rigel D.S. The immediate impact of COVID-19 on U.S. dermatology practices. J Am Acad Dermatol. 2020;83(2):685–686. doi: 10.1016/j.jaad.2020.05.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Madigan L.M., Micheletti R.G., Shinkai K. How dermatologists can learn and contribute at the leading edge of the COVID-19 global pandemic. JAMA Dermatol. 2020;156(7):733–734. doi: 10.1001/jamadermatol.2020.1438. [DOI] [PubMed] [Google Scholar]
  31. Mahmood S., Hasan K., Colder Carras M., Labrique A. global preparedness against COVID-19: We must leverage the power of digital health. JMIR Public Health Surveill. 2020;6(2) doi: 10.2196/18980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Marchell R., Locatis C., Burgess G., Maisiak R., Liu W.L., Ackerman M. Patient and provider satisfaction with teledermatology. Telemed J E Health. 2017;23(8):684–690. doi: 10.1089/tmj.2016.0192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mounessa J.S., Chapman S., Braunberger T., Qin R., Lipoff J.B., Dellavalle R.P. A systematic review of satisfaction with teledermatology. J Telemed Telecare. 2018;24(4):263–270. doi: 10.1177/1357633X17696587. [DOI] [PubMed] [Google Scholar]
  34. Muddasani S., Housholder A., Fleischer A.B. An assessment of United States dermatology practices during the COVID-19 outbreak. J Dermatolog Treat. 2020;31(5):436–438. doi: 10.1080/09546634.2020.1750556. [DOI] [PubMed] [Google Scholar]
  35. National Comprehensive Cancer Network. Advisory statement for non-melanoma skin cancer care during the COVID-19 pandemic [Internet]. 2020 [cited 2020 June 12]. Available at: https://www.nccn.org/covid-19/pdf/NCCN-NMSC.pdf.
  36. National Comprehensive Cancer Network. Short-term recommendations for cutaneous melanoma management during COVID-19 pandemic [Internet]. 2020 [cited 2020 June 16]. Available at: https://www.nccn.org/covid-19/pdf/Melanoma.pdf.
  37. Radi G., Diotallevi F., Campanati A., Offidani A. Global coronavirus pandemic (2019-nCOV): Implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020;34(5):e213–e214. doi: 10.1111/jdv.16386. [DOI] [PubMed] [Google Scholar]
  38. Sheriff T., Murrell O.G., Murrell D.F. Restructuring an academic dermatology practice during the COVID-19 pandemic. Dermatol Ther. 2020 doi: 10.1111/dth.13684. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tao J., Song Z., Yang L., Huang C., Feng A., Man X. Emergency management for preventing and controlling nosocomial infection of the 2019 novel coronavirus: Implications for the dermatology department. Br J Dermatol. 2020;182(6):1477–1478. doi: 10.1111/bjd.19011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Temiz S.A., Dursun R., Daye M., Ataseven A. Evaluation of dermatology consultations in the era of COVID-19. Dermatol Ther. 2020 doi: 10.1111/dth.13642. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tolles J., Meurer W.J. Logistic regression: Relating patient characteristics to outcomes. JAMA. 2016;316(5):533–534. doi: 10.1001/jama.2016.7653. [DOI] [PubMed] [Google Scholar]
  42. Villani A., Scalvenzi M., Fabbrocini G. Teledermatology: A useful tool to fight COVID-19. J Dermatolog Treat. 2020;31(4):325. doi: 10.1080/09546634.2020.1750557. [DOI] [PubMed] [Google Scholar]
  43. Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther. 2020 doi: 10.1111/dth.13430. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Yan Y., Chen H., Chen L., Cheng B., Diao P., Dong L. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019. Dermatol Ther. 2020 doi: 10.1111/dth.13310. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zheng Y., Lai W. Dermatology staff participate in fight against Covid-19 in China. J Eur Acad Dermatol Venereol. 2020;34(5):e210–e211. doi: 10.1111/jdv.16390. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Women's Dermatology are provided here courtesy of Wolters Kluwer Health

RESOURCES